Literature DB >> 25499951

Risk-directed therapy and research in neuroblastoma.

Yen-Lin Liu1, James S Miser2, Wen-Ming Hsu3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25499951     DOI: 10.1016/j.jfma.2014.11.001

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


× No keyword cloud information.
  3 in total

Review 1.  Protein glycosylation in cancers and its potential therapeutic applications in neuroblastoma.

Authors:  Wan-Ling Ho; Wen-Ming Hsu; Min-Chuan Huang; Kenji Kadomatsu; Akira Nakagawara
Journal:  J Hematol Oncol       Date:  2016-09-29       Impact factor: 17.388

2.  Diagnostic FDG and FDOPA positron emission tomography scans distinguish the genomic type and treatment outcome of neuroblastoma.

Authors:  Yen-Lin Liu; Meng-Yao Lu; Hsiu-Hao Chang; Ching-Chu Lu; Dong-Tsamn Lin; Shiann-Tarng Jou; Yung-Li Yang; Ya-Ling Lee; Shiu-Feng Huang; Yung-Ming Jeng; Hsinyu Lee; James S Miser; Kai-Hsin Lin; Yung-Feng Liao; Wen-Ming Hsu; Kai-Yuan Tzen
Journal:  Oncotarget       Date:  2016-04-05

3.  VEGF expression correlates with neuronal differentiation and predicts a favorable prognosis in patients with neuroblastoma.

Authors:  Wen-Chin Weng; Kuan-Hung Lin; Pei-Yi Wu; Ya-Hsuan Ho; Yen-Lin Liu; Bo-Jeng Wang; Chien-Chin Chen; Yueh-Chien Lin; Yung-Feng Liao; Wang-Tso Lee; Wen-Ming Hsu; Hsinyu Lee
Journal:  Sci Rep       Date:  2017-09-11       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.